Healthcare Industry News: Getinge
News Release - March 29, 2016
Getinge Group Receives Innovative Technology Designation from Novation for the Maquet InterValve V8(TM) Balloon Aortic Valvuloplasty Catheter and the Maquet ClearFlow PleuraFlow(R) Active Clearance Technology(R) (ACT(TM)) SystemDesignation recognizes the development of new solutions that benefit the healthcare industry
WAYNE, N.J., March 29, 2016 -- (Healthcare Sales & Marketing Network) -- Getinge Group announced its Maquet V8 Catheter and Maquet PleuraFlow Active Clearance Technology System have received Innovative Technology designation from Novation, the leading healthcare services company that serves the more than 100,000 members and affiliates of VHA Inc., UHC, Children's Hospital Association, and Provista. The designation was based on reviews of the V8 Catheter and the PleuraFlow System by hospital experts who attended Novation's Innovative Technology Expo in November 2015. The annual event provides medical technology suppliers with the opportunity to demonstrate product and gain direct feedback from onsite clinical experts and healthcare providers regarding the impact their products may have on improving safety, efficacy or clinical outcomes, as well as possible business model and process efficiencies that enhance the overall level of care offered by the organization.
V8 Balloon Aortic Valvuloplasty Catheter
- Unique: The figure 8–shaped balloon is designed to lock into valve anatomy limiting balloon movement during the procedure
- Safe: The balloon shape is maintained throughout inflation reducing the likelihood of annular rupture
- Effective: The balloon enhances leaflet hyperextension without increasing the risk of annulus over-distension
- Fast: The balloon allows rapid inflate/deflate times
PleuraFlow Active Clearance Technology (ACT) System
- Unique: Innovative technology used to proactively maintain drainage-catheter patency to ensure optimal evacuation of blood and fluids from the chest cavity after cardiothoracic surgery
- Cost Effective: Has been shown to substantially reduce Retained Blood Syndrome (RBS) re-interventions compared to conventional chest tubes1 2 3
- Clinically Effective: A recent clinical evaluation published in JTCVS showed reduced RBS re-interventions and postoperative A-Fib (POAF) in patients with use of the PleuraFlow System4
"Novation is committed to providing the members we serve with leading-edge technologies that deliver new clinical and operational benefits from what is currently available in the market today," said Debbie Archer, Director of Procurement and leader of the Innovative Technology Program for suppliers. "After reviewing both of Maquet's product entries at our annual Innovative Expo, the hospital experts who attended agreed both products offer unique and incremental benefits over other products available on the market today, and recommended them for the Innovative Technology designation."
Since 2003, more than 2,000 new and innovative products and technologies have been submitted through the Novation Innovative Technology Program. Novation works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Novation's competitive bid cycle.
To learn more about Novation's Innovative Technology program, visit www.novationco.com/expertise/technology.
About Getinge Group
Getinge Group is a leading global provider of innovative solutions for operating rooms, intensive-care units, hospital wards, sterilization departments, elderly care and for life science companies and institutions. With a genuine passion for life we build quality and safety into every system. Our unique value proposition mirrors the continuum of care, enhancing efficiency throughout the clinical pathway. Based on our first-hand experience and close partnerships, we are able to exceed expectations from customers – improving the every-day life for people, today and tomorrow.
1 Timothy L. Frankel; Peter C. Hill; Sotiris C. Stamou; Robert C. Lowery; Albert J. Pfister; Arvind Jain; and Paul J. Corso. Silastic Drains vs Conventional Chest Tubes After Coronary Artery Bypass. CHEST 124(2003) 108--113.
2 Based on over 313,000 US adult heart surgery patients. Data extracted using ICD--9 codes from the 2010 Nationwide Inpatient Sample (NIS), from the DHHS Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP).
3 Karimov, J.H., Gillinov, A.M., Schenck, L., et al. Incidence of chest tube clogging after cardiac surgery: a single--centre prospective observational study. Eur J Cardiothorac Surg. 2013 Dec;44(6):1029--36. dos:10.1093/ejcts/ezt140.
4 Active clearance of chest drainage catheters reduces retained blood, Sirch, Joachim et al., The Journal of Thoracic and Cardiovascular Surgery , E-Pub October 16, 2015
Source: Getinge Group
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.